Drug intelligence / Profile preview

RHA Collection

Development stage
Unknown
Lead developer
Teoxane
Modality
Recombinant Proteins and Enzymes
Administration
Intradermal, Subcutaneous, Submucosal
01

Overview

The RHA Collection is a family of injectable dermal fillers composed of resilient hyaluronic acid (RHA), designed specifically for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds. These fillers are formulated using a gentle manufacturing process that preserves the natural structure of hyaluronic acid, allowing them to more closely mimic the HA naturally found in human skin. This design enables the fillers to adapt to facial movements for a natural look both at rest and in motion. The collection includes several formulations—RHA 2, RHA 3, RHA 4, and RHA Redensity—each tailored for different depths and severities of wrinkles or volume loss. The mechanism involves providing structural support by supplementing lost or diminished hyaluronic acid in the skin’s dermal layers[3][5][6][7]. The product is FDA-approved for use in adults aged 22 years or older.

Brand names
RHA CollectionTeoxane RHA Collection
Other names
Resilient Hyaluronic Acid CollectionRHA fillers
02

Targets

ICAM1 (Intercellular Adhesion Molecule 1)RHAMM (Hyaluronan-mediated motility receptor)CD44 (CD44 antigen)

Beyond the preview

Go deeper on RHA Collection.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RHA Collection.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call